CHROMR and diffuse large B-cell lymphoma: CD20 expression was significantly elevated in the shCHROMR group compared with the shNC group without the treatment of rituximab, and was marked reduced in the shCHROMR group after the treatment of rituximab (20 μg/ml) by RT-qPCR (Fig. 2, A and B) and western blotting (Fig. 2C), suggesting that lncRNA CHROMR suppression enhanced CD20 expression and sensitized DLBCL cells to rituximab.